Key players such as Hansa Biopharma [Idefirix (imlifidase)], CSL Behring [clazakizumab], Talaris Therapeutics [FCR001)], and a few others are investigating their candidates to manage AMR. The projected introduction of these drugs might get an advantage in market space in due course.
DelveInsight’s “Antibody-mediated Rejection Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Antibody-mediated Rejection market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Antibody-mediated Rejection market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Antibody-mediated Rejection: An Overview
Antibody‐mediated rejection (AMR) is a significant complication following organ transplantation that contributes to short‐ and long‐term injury in transplant recipients. Despite desensitization protocols, up to one‐third of highly sensitized recipients may develop acute AMR following transplantation. AMR is also of significant concern in non-sensitized individuals, as de novo DSAs can develop early or late after transplantation.
AMR episodes occurring at different periods seem to be different clinical sub-entities. Early AMR is usually correlated with sensitization, pre-existing alloantibodies, and rapid graft dysfunction and is usually easy to be controlled; while late AMR is mostly correlated with withdrawal or reduction of immunosuppressants and noncompliance with immunosuppressive therapy, whereas late AMR has little response to antirejection strategies and thus correlate with poor graft outcomes.
Antibody-mediated Rejection Market Key Facts
The total market size of Antibody-Mediated Rejection in the United States accounted for USD 65.58 million in 2021, which is expected to rise during the study period (2019–2032).
In EU5, the total market size of Antibody-Mediated Rejection was USD 20.50 million in 2021.
In Japan, the total market size of Antibody-Mediated Rejection was USD 2.24 million in 2021.
In the year 2021, the total cases of Antibody-Mediated Rejection were 5,102 in the 7MM.
As per the DelveInsight estimates, the United States showed the highest incident population with AMR cases. In 2021, the total incidence of AMR cases in the United States was found to be 3,327 cases, which as per DelveInsight’s estimates, will increase at a moderate CAGR by 2032.
Total cases of Antibody-Mediated Rejection (AMR) in EU5 countries were found to be 1,600 cases in 2021, which is expected to increase at a moderate CAGR for the study period, i.e. 2019–2032.
Antibody-mediated Rejection Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Antibody-mediated Rejection market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Antibody-mediated Rejection market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Antibody-mediated Rejection Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Antibody-mediated Rejection Epidemiology, Segmented as –
Total Transplant Incidence Cases in the 7MM [2019–2032]
Total Cases of Antibody-Mediated Rejection (AMR) in the 7MM [2019–2032]
Antibody-mediated Rejection Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Antibody-mediated Rejection market or expected to be launched during the study period. The analysis covers the Antibody-mediated Rejection market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Antibody-mediated Rejection pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Antibody-mediated Rejection Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market
Antibody-mediated Rejection Therapeutics Market
The Leading Players in the Antibody-mediated Rejection Therapeutics Market Include:
CSL Behring
Hansa Biopharma
Sanofi
Talaris Therapeutics
Horizon Therapeutics
And Many Others
Antibody-mediated Rejection Therapies Covered in the Report Include:
Clazakizumab: CSL Behring
Imlifidase: Hansa Biopharma
BIVV020: Sanofi
FCR001: Talaris Therapeutics
Dazodalibep (VIB4920): Horizon Therapeutics
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Antibody-mediated Rejection Competitive Intelligence Analysis
4. Antibody-mediated Rejection Market Overview at a Glance
5. Antibody-mediated Rejection Disease Background and Overview
6. Antibody-mediated Rejection Patient Journey
7. Antibody-mediated Rejection Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Antibody-mediated Rejection Treatment Algorithm, Current Treatment, and Medical Practices
9. Antibody-mediated Rejection Unmet Needs
10. Key Endpoints of Antibody-mediated Rejection Treatment
11. Antibody-mediated Rejection Marketed Products
12. Antibody-mediated Rejection Emerging Drugs and Latest Therapeutic Advances
13. Antibody-mediated Rejection Seven Major Market Analysis
14. Attribute Analysis
15. Antibody-mediated Rejection Market Outlook (In US, EU5, and Japan)
16. Antibody-mediated Rejection Access and Reimbursement Overview
17. KOL Views on the Antibody-mediated Rejection Market
18. Antibody-mediated Rejection Market Drivers
19. Antibody-mediated Rejection Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Take control of your pharmaceutical portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your pharmaceutical portfolio today @ Pharmaceutical Portfolio Management Strategies
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
